pharmaphorum

Compass points to strong psilocybin data in depression

Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...
Investing

Stifel reiterates Compass Therapeutics stock rating ahead of trial data

Investing.com - Stifel reiterated a Buy rating and $12.00 price target on Compass Therapeutics (NASDAQ:CMPX) shares, well above the current stock price of $5.10. The biotech company has delivered a ...
Investing

Compass Point reiterates Applied Digital stock rating on data center growth

Investing.com - Compass Point reiterated a Buy rating and $45 price target on Applied Digital (NASDAQ:APLD) following the company’s fiscal third-quarter results. The stock currently trades at $27.79, ...
The Business Journals

San Francisco home prices hit new high, with sales soaring past $2 million on average

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min San Francisco's housing market ...